Inhibikase Therapeutics Inc. Financials
IKT
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM ~1.8:1 split | DEC 2025 4:1 split | DEC 2024 ~4.4:1 split | DEC 2023 | DEC 2022 ~1.4:1 split | DEC 2021 ~2.2:1 split |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $0 | – | $0 | $0 | $0 | $3 |
| Cost of Revenue | -$1 | -$1 | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | – | $0 | $0 | $0 | $3 |
| General & Administrative | $27 | $24 | $11 | $7 | $6 | $7 |
| Research & Development | $37 | $30 | $17 | $14 | $12 | $11 |
| Total Operating Expenses | $62 | $52 | $29 | $20 | $18 | $18 |
| Operating Income | -$62 | -$52 | -$29 | -$20 | -$18 | -$15 |
| Non-Operating | ||||||
| Net Interest Expense | – | – | – | – | – | -$0 |
| EBT (Earnings Before Tax) | – | -$0 | -$0 | – | – | – |
| Income Tax Expense | $0 | $0 | $0 | – | – | – |
| Net Income | ||||||
| Net Income | -$58 | -$48 | -$28 | -$19 | -$18 | -$15 |
| Per Share Data | ||||||
| Revenue Per Share | $0.00 | – | $0.00 | $0.05 | $0.03 | $1.02 |
| EPS (Basic) | -$0.45 | -$0.49 | -$1.16 | -$3.16 | -$4.28 | -$4.86 |
| EPS (Diluted) | -$0.45 | -$0.49 | -$1.16 | -$3.16 | -$4.28 | -$4.86 |
| Weighted Avg Shares (Basic) | 174.6M | 98.3M | 23.7M | 5.3M | 25.2M | 18.2M |
| Weighted Avg Shares (Diluted) | 174.6M | 98.3M | 23.7M | 5.3M | 25.2M | 18.2M |
| Shares Outstanding | 174.6M | 98.3M | 23.7M | 5.3M | 4.2M | 3.0M |
Inhibikase Therapeutics (IKT) financials: revenue, profit and margins
Inhibikase Therapeutics (IKT) generated about n/a in revenue and -$69 million in net income over the trailing twelve months, growing at roughly -28.0% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Inhibikase Therapeutics profitable?+
Inhibikase Therapeutics reported about -$69 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is Inhibikase Therapeutics growing?+
Inhibikase Therapeutics's revenue has compounded at roughly -28.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside IKT's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 2 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 10 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with IKT
Held by ETFs
IKT is in 3 US ETFs. The largest of them, with IKT's weight in each:
Spot a number that looks wrong? Check it in IKT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IKT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.